Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs
DOI: https://doi.org/10.2147/dddt.s462785
IF: 4.3188
2024-06-12
Drug Design Development and Therapy
Abstract:Hongqing Zhao, 1, 2, &ast Yang Liu, 1, 2, &ast Na Cai, 3 Xiaolin Liao, 1, 2 Lin Tang, 2, 4 Yuhong Wang 1, 2 1 Science & Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China; 2 Hunan Key Laboratory of Traditional Chinese Medicine Prevention & Treatment of Depressive Diseases, Changsha, Hunan, People's Republic of China; 3 Outpatient Department, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China; 4 Department of Pharmacy, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lin Tang; Yuhong Wang, Email ; Over the past decade, the idea of targeting the endocannabinoid system to treat anxiety disorders has received increasing attention. Previous studies focused more on developing cannabinoid receptor agonists or supplementing exogenous cannabinoids, which are prone to various adverse effects due to their strong pharmacological activity and poor receptor selectivity, limiting their application in clinical research. Endocannabinoid hydrolase inhibitors are considered to be the most promising development strategies for the treatment of anxiety disorders. More recent efforts have emphasized that inhibition of two major endogenous cannabinoid hydrolases, monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), indirectly activates cannabinoid receptors by increasing endogenous cannabinoid levels in the synaptic gap, circumventing receptor desensitization resulting from direct enhancement of endogenous cannabinoid signaling. In this review, we comprehensively summarize the anxiolytic effects of MAGL and FAAH inhibitors and their potential pharmacological mechanisms, highlight reported novel inhibitors or natural products, and provide an outlook on future directions in this field. Keywords: endocannabinoid hydrolase inhibitors, endocannabinoid system, anxiety disorders, anxiolytic, MAGL, FAAH Anxiety disorders represent prevalent mental health conditions characterized by persistent psychogenic anxiety, somatic anxiety, and sleep disorders. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the classification of anxiety disorders includes Generalized Anxiety Disorder, Phobias (including specific phobias and social anxiety disorder), Panic Disorder, as well as other anxiety-related conditions such as Separation Anxiety Disorder and Selective Mutism. 1 The global prevalence of anxiety disorders ranges from 7.3% to 28.0%, making them a significant concern worldwide. 2 Specifically, in China, anxiety disorders stand out as the most prevalent mental illness, with a lifetime incidence of 7.6%. 3 The World Health Organization underscores the significance of anxiety disorders by ranking them as the sixth leading contributor to global disability, establishing it as a pressing health and wellness concern that demands attention. 4 Regrettably, the existing repertoire of anxiolytic medications faces challenges in adequately addressing the needs of the extensive population affected by anxiety disorders. 5 Benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) antidepressants are the primary drugs employed clinically for the treatment of anxiety disorders. 6,7 However, their anxiolytic effects are secondary indications rather than primary, and the drugs, especially benzodiazepines, are subject to stringent controls and possess potential addictive properties. 8 Consequently, the development of novel drugs targeting anxiety disorders remains a focal point in the ongoing research and development of psychotropic medications. Traditionally, anxiolytic drug development focused on neurotransmitter-based hypotheses, yielding medications like eszopiclone and buspirone. 9,10 Recent attention has turned to novel approaches, particularly targeting the endocannabinoid system (ECS). The ECS, integral to mood regulation, has been implicated in the pathogenesis of both anxiety and depression, underscoring its potential as a novel therapeutic frontier. 11 Novel drug designs that target the ECS are considered to be the most promising candidates for the treatment of anxiety disorders. 12 Studies explore ECS modulation for anxiolysis, including increasing endogenous cannabinoids (eCBs) secretion and inhibiting their hydrolase enzymes. However, challenges arise due to the unique characteristics of endocannabinoids. Efforts to develop c -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal